BackStop Neural Welcomes Dr. Kasra Amirdelfan to Technical Advisory Board

Dr. Kasra Amirdelfan is a founding partner of IPM Medical Group, Inc., and he holds special interest in spinal cord stimulation, spinal diseases, and stem cell technologies.

April 22, 2025 — BackStop Neural is proud to announce that Dr. Kasra Amirdelfan has joined its Technical Advisory Board, bringing unparalleled expertise in pain management and spinal cord stimulation to the company. Dr. Amirdelfan is a board-certified pain medicine specialist and a founding partner of Boomerang Healthcare, Inc. With decades of experience, he has been at the forefront of advancing interventional pain therapies, pioneering research, and guiding clinical innovations that have transformed the field.

"I am excited to join BackStop Neural and collaborate on advancing spinal cord stimulation technology to improve patient outcomes,” said Dr. Amirdelfan. “BackStop Neural’s innovative approach aligns with my passion for expanding what is possible in neuromodulation and pain medicine.”

Dr. Amirdelfan completed his medical degree at Texas A&M University, followed by a residency at John Peter Smith Hospital and a fellowship in interventional pain management under Dr. Elliot Krames, one of the pioneers of neuromodulation. He has served as Department Chair of Pain Medicine at esteemed institutions, presented his expertise at national and international conferences, and contributed extensively to research aimed at improving pain management therapies worldwide.

“Dr. Amirdelfan’s deep clinical insight and vast experience in spinal cord stimulation will be instrumental in shaping our next-generation technologies,” said Kial Gramley, Chief Product Officer of BackStop Neural. “His leadership in the pain management community will provide invaluable guidance as we push forward with our mission to expand the eligible patient population for SCS and enhance safety.”

BackStop Neural is developing thin-film spinal cord stimulation leads to expand treatment options for chronic pain patients and enhance the safety and effectiveness of neuromodulation therapy.